WASHINGTON - The U.S. Food and Drug Administration (FDA) rescinded its emergency use authorization of hydroxychloroquine and chloroquine to treat COVID-19 patients.Based on FDA’s continued review of the scientific evidence available for hydroxychloroquine sulfate (HCQ) and chloroquine phosphate (CQ) to treat COVID-19, FDA has determined that the statutory criteria for EUA as outlined in Section 564(c)(2) of the Food, Drug, and Cosmetic Act are no longer met,“ the FDA wrote in a June 15 update.